Bioanalytical
Biologically active substances 'offer range of benefits'
Feb 18 2011
Six separate papers have been published following studies conducted at the Institut de recherches cliniques de Montreal (IRCM), all focusing on a group of PCSK enzymes.
PCSK9 - a Proprotein Convertase, Subtilisin/Kexin enzyme - is of particular interest for research relating to potential health benefits in humans.
The IRCM team, led by Dr Nabil G Seidah, the institute's Biochemical Neuroendocrinology research unit director, linked it with limited generation of fat and maintenance of high levels of circulating cholesterol.
Meanwhile, other biologically active substances in the PCSK family were found to interact with PCSK9, cutting and inactivating it.
Learning more about these processes could lead to therapies for viruses, cancer, neuroendocrine disorders and cardiovascular disease.
The IRCM is about to celebrate its 60th anniversary, having been devised in 1951 by Jacques Genest and set up formally the following year.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Apr 09 2024 Munich, Germany
Apr 23 2024 Kintex, South Korea
Apr 23 2024 Seoul, South Korea
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain